Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
about
Toll-like receptors: the swiss army knife of immunity and vaccine developmentAwareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studiesGynecological cancers: A summary of published Indian dataVaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacyImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsPooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programmeSafety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studiesImmunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh.Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis.Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global reviewLiterature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trialsRecent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Insect cell technology is a versatile and robust vaccine manufacturing platform.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series.Human papillomavirus infection among young adolescents in India: impact of vaccination.Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India.
P2860
Q26746644-323FD736-7322-47AA-B036-CB8FA0D22295Q28066373-CFA988E3-82BF-48E7-AC94-FFDDB7B2854AQ28069130-A035A31E-309F-41A9-97B3-CBF580CEF92BQ28084836-8ABA9390-4F4E-49FC-A768-E6FB398FBD5CQ28972540-52E4494E-C72C-4BB7-8FAD-25FC77F1A100Q30780649-965AFC2A-1B28-40FF-BA15-03989B8396C2Q33891821-6A94683F-6394-4BC7-8F78-9360702099E8Q34291136-BB37C3EF-8F73-4DF7-9CEF-17C061BD2F19Q35630515-412B0309-C6A6-4E4E-8338-BC6408FE4424Q36237280-4E179CE5-01F7-4C3F-A6B8-6351F24C6713Q36609068-32595ABB-4D60-401A-9DA5-94A985DD9C26Q37425284-1C1324BA-E56D-42C4-90A7-E21798102E14Q37867102-C8B70FF4-95C5-47CE-BEA9-23FC9038D126Q37909427-C2A347E2-C64B-445A-92FF-852C35028FC0Q38370782-FD6CC618-5221-42D9-8883-24DCC85B5140Q38668821-5417EA7E-3172-42A9-B92E-97F4D9A3D8C3Q45392523-70BA68B0-BBF3-4239-9D52-E17974D02453Q52631712-D94941B5-7E00-4AA9-B8F0-603E2B4240F2
P2860
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Immunogenicity and safety of h ...... ccine in healthy Indian women.
@en
type
label
Immunogenicity and safety of h ...... ccine in healthy Indian women.
@en
prefLabel
Immunogenicity and safety of h ...... ccine in healthy Indian women.
@en
P2093
P2860
P1476
Immunogenicity and safety of h ...... ccine in healthy Indian women.
@en
P2093
Dominique J Descamps
Hans L Bock
Indian HPV Vaccine Study Group
Partha Basu
Sanjoy K Datta
Surendra Shastri
Vanita Suri
P2860
P304
P356
10.1111/J.1447-0756.2009.01167.X
P577
2010-02-01T00:00:00Z